Puretech founded entity karuna therapeutics announces new england journal of medicine publication of data from emergent-1 phase 2 trial evaluating karxt in schizophrenia

Boston--(business wire)--puretech health plc (nasdaq: prtc, lse: prtc) (“puretech” or the “company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its founded entity, karuna therapeutics, inc. (nasdaq: krtx), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condit
PRTC Ratings Summary
PRTC Quant Ranking